Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
There are no available medical treatment options for patients with non-functioning pituitary
adenomas (NFPA) or with resistant prolactinomas to dopamine agonists (DA) who are not cured
by surgery. The study of the receptors by quantitative messenger ribonucleic acid (mRNA)
expression levels and immunohistochemistry analysis might end with a better understanding of
these tumors. Besides that, it will be assessed the in vitro and in vivo responses to
pasireotide (for NFPA and prolactinomas) and cabergoline (for NFPA). These responses will be
compared with the receptor expressions which may be a tool as a predicting element of the
response to these compounds.